Related Experiment Video
Updated: Mar 31, 2026
09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
28.0K
[Drug dosage in obese children]
Christina Gade1, Hanne Rolighed Christensen, Helle Holst
1christina.gade@regionh.dk.
Ugeskrift for Laeger
|October 29, 2015
Summary
Childhood obesity is rising globally, leading to increased medication use. Understanding how obesity affects drug metabolism is crucial for safe and effective pediatric dosing, preventing undertreatment and toxicity.
Area of Science:
- Pediatric pharmacology
- Obesity research
- Drug metabolism
Background:
- Childhood obesity is a growing global health concern.
- Obese children exhibit altered physiology compared to normal-weight children.
- Increased medication use is observed in obese pediatric populations.
Purpose of the Study:
- To investigate the impact of obesity-related physiological changes on drug metabolism in children.
- To highlight the need for specialized pharmacokinetic studies in obese children.
- To address the knowledge gap in pediatric drug dosing for obese individuals.
Main Methods:
- Review of existing literature on physiological alterations in obese children.
- Analysis of the implications of these alterations for drug pharmacokinetics.
- Identification of the need for specific pharmacokinetic studies.
Main Results:
- Obesity causes physiological changes that can significantly alter drug metabolism.
- Current understanding of drug metabolism in obese children is limited.
- Consequences for drug dosing, including undertreatment and toxicity, are poorly understood.
Conclusions:
- Pharmacokinetic studies are essential to optimize drug therapy in obese children.
- Addressing this knowledge gap is critical for patient safety and treatment efficacy.
- Further research is needed to establish evidence-based dosing guidelines.
Related Concept Videos
01:21Drug Dosing: Obese Patients
339
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
339
01:29Drug Dosing: Infants and Children
751
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
751
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
381
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
381
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
282
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
282
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
373
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
373